AI English summary of an SEC filing — figures as filed
Bio-Techne TECHBio-Techne said net sales for the quarter ended December 31, 2024 (Q2 of fiscal 2025) increased 9% to $297.0 million. Organic revenue also increased 9%. The company said foreign currency exchange and a business held-for-sale did not have a material impact.
Key points
AI summaryBio-Techne said net sales for the quarter ended December 31, 2024 (Q2 of fiscal 2025) increased 9% to $297.0 million. Organic revenue also increased 9%. The company said foreign currency exchange and a business held-for-sale did not have a material impact.
The company said GAAP operating income for the quarter increased 25% to $47.4 million, and adjusted operating income increased 8% to $88.7 million. GAAP diluted EPS was $0.22 compared to $0.17 in the prior year quarter, and adjusted EPS was $0.42 compared to $0.40 in the prior year quarter.
Bio-Techne said Protein Sciences segment net sales for the quarter were $211.6 million, an increase of 7% with operating margin of 41.2%, and Diagnostics and Spatial Biology segment net sales were $84.1 million, an increase of 12% with operating margin of 3.9%. The company cited reinstatement of incentive compensation accruals as a margin factor for both segments.
Bio-Techne disclosed that operating cash flow for the 6 months ended December 31, 2024 was $148,235 thousand. The company used $75,628 thousand for share repurchases and $25,424 thousand for cash dividends during the period. Cash and cash equivalents at the end of the period were $177,549 thousand.
Summary
AI-writtenAnalysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.
Fiscal 2025 Q2 Net Sales $297.0 million
Bio-Techne said net sales for the quarter ended December 31, 2024 (Q2 of fiscal 2025) increased 9% to $297.0 million. Organic revenue also increased 9%. The company said foreign currency exchange and a business held-for-sale did not have a material impact.
Source · Based on the filing body and exhibits
GAAP Operating Income $47.4 million, Adjusted Operating Income $88.7 million
The company said GAAP operating income for the quarter increased 25% to $47.4 million, and adjusted operating income increased 8% to $88.7 million. GAAP diluted EPS was $0.22 compared to $0.17 in the prior year quarter, and adjusted EPS was $0.42 compared to $0.40 in the prior year quarter.
Source · Based on the filing body and exhibits
Segment Revenue and Operating Margin
Bio-Techne said Protein Sciences segment net sales for the quarter were $211.6 million, an increase of 7% with operating margin of 41.2%, and Diagnostics and Spatial Biology segment net sales were $84.1 million, an increase of 12% with operating margin of 3.9%. The company cited reinstatement of incentive compensation accruals as a margin factor for both segments.
Source · Based on the filing body and exhibits
6 Months Operating Cash Flow and Use of Funds
Bio-Techne disclosed that operating cash flow for the 6 months ended December 31, 2024 was $148,235 thousand. The company used $75,628 thousand for share repurchases and $25,424 thousand for cash dividends during the period. Cash and cash equivalents at the end of the period were $177,549 thousand.
Source · Based on the filing body and exhibits
AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.
Original filing
The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.
Loading the filing text…